REGULAR STRENGTH ANALGESIC & MUSCLE RELAXANT CAPLETS TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
22-03-2013
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
IBUPROFEN; METHOCARBAMOL
Tilgjengelig fra:
TEVA CANADA LIMITED
ATC-kode:
M03BA53
INN (International Name):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dosering :
200MG; 500MG
Legemiddelform:
TABLET
Sammensetning:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Administreringsrute:
ORAL
Enheter i pakken:
18/40
Resept typen:
OTC
Terapeutisk område:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Produkt oppsummering:
Active ingredient group (AIG) number: 0248961001; AHFS:
Autorisasjon status:
CANCELLED PRE MARKET
Autorisasjon dato:
2015-11-25
Preparatomtale
IMPORTANT: PLEASE READ
1 | P a g e
PRODUCT MONOGRAPH
REGULAR STRENGTH ANALGESIC & MUSCLE
RELAXANT CAPLETS
METHOCARBAMOL AND IBUPROFEN TABLETS
500 MG/200 MG
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED,
Date of Preparation:
30 Novopharm Court
March 5, 2013
Toronto, Canada
M1B 2K9
Control# 161027
IMPORTANT: PLEASE READ
2 | P a g e
TABLE
OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
ADVERSE
REACTIONS..................................................................................................10
DRUG
INTERACTIONS..................................................................................................12
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
...............................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
...........................................................18
STORAGE AND
STABILITY.........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................22
PART II: SCIENTIFIC
INFORMATION....................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..........................................................................................................23
DETAILED
PHARMACOLOGY........................................
Les hele dokumentet
